Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €11.37 EUR
Change Today +0.03 / 0.26%
Volume 3.1K
As of 11:13 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

kiadis pharma nv (KDS) Snapshot

Open
€11.26
Previous Close
€11.34
Day High
€11.40
Day Low
€11.15
52 Week High
07/2/15 - €12.85
52 Week Low
08/24/15 - €10.55
Market Cap
153.1M
Average Volume 10 Days
3.7K
EPS TTM
--
Shares Outstanding
13.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KIADIS PHARMA NV (KDS)

Related News

No related news articles were found.

kiadis pharma nv (KDS) Related Businessweek News

No Related Businessweek News Found

kiadis pharma nv (KDS) Details

Kiadis Pharma N.V. researches, develops, and commercializes cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products provide for Allodepleted T-cell ImmunotheRapeutics (ATIR). The company offers ATIR101 that addresses the risks and limitations of current hematopoietic stem cell transplantation treatments in blood cancers. The company also develops ATIR201 for inherited blood disorders with an initial focus on thalassemia. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam-Duivendrecht, the Netherlands.

23 Employees
Last Reported Date: 08/25/15
Founded in 1997

kiadis pharma nv (KDS) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €365.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €170.9K
Compensation as of Fiscal Year 2014.

kiadis pharma nv (KDS) Key Developments

Kiadis Pharma N.V. Announces Maiden Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Kiadis Pharma N.V. announced maiden unaudited consolidated earnings results for the six months ended June 30, 2015. For the six months, the company reported operating loss of €11.7 million against €2.9 million a year ago. Loss attributable to owners of the company was €9.6 million or €0.85 per diluted share against €3.5 million or €0.31 per diluted share a year ago. Net cash used in operating activities was €3.6 million against €2.7 million a year ago. Loss before tax was €9.6 million against €3.5 million last year. Acquisition of PP&E was €0.02 million against €0.1 million last year.

Kiadis Pharma Announces Full Enrolment of its Phase II Clinical Study with Lead Product, ATIR101™

Kiadis Pharma N.V. announced full enrol­ment of patients into its ongo­ing Phase II clin­i­cal study with its lead prod­uct, ATIR101™. ATIR101™ is a cell-based prod­uct designed to enable stem cell trans­plan­ta­tions from par­tially matched (hap­loiden­ti­cal) fam­ily donors for blood can­cer patients who do not have a match­ing stem cell donor avail­able. The ongo­ing Phase II study with ATIR101™ is an inter­na­tional multi-centre study in which a total of 23 leukaemia patients, includ­ing patients with acute myeloid leukaemia (AML), acute lym­phoblas­tic leukaemia (ALL) and myelodys­plas­tic syn­drome (MDS), will be enrolled and treated with ATIR101™ as part of their trans­plant reg­i­men. The pri­mary end­point of the study is the rate of Transplant Related Mortality (TRM) at six months after all­o­goneic hematopoi­etic stem cell trans­plan­ta­tion (HSCT). To date, 21 out of the 23 enrolled patients have received their HSCT, 19 of which have also been dosed with ATIR101™. The remain­ing patients are at var­i­ous stages of treat­ment, either being pre­pared for HSCT or being dosed with ATIR101™. The 23rd patient is expected to undergo treat­ment with ATIR101™ in the third quarter 2015 and the study will remain open for enrol­ment until this final patient has been treated. Read-out of the pri­mary end­point results is expected in the first quarter 2016.

Kiadis Pharma N.V. Auditor Raises 'Going Concern' Doubt

Kiadis Pharma N.V. filed its Annual on Jun 17, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KDS:NA €11.37 EUR +0.03

KDS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDS.
View Industry Companies
 

Industry Analysis

KDS

Industry Average

Valuation KDS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KIADIS PHARMA NV, please visit www.kiadis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.